1. Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes 
Lan-Ping Xu, Chun-Li Zhang, Xiao-Dong Mo, Xiao-Hui Zhang, Huan Chen, Wei Han, Yu-Hong Chen, Yu Wang, Chen-Hua Yan, Jing-Zhi Wang, Feng-Rong Wang, Ting Zhao, Yan-Rong Liu, Kai-Yan Liu, Xiao-Jun Huang 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 12, Pages (December 2015)
DOI: /j.bbmt
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Kaplan-Meier estimates of overall survival for (A) non-PTLD and (B) PTLD probable and proven PTLD patients.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Kaplan–Meier estimates of overall survival for PTLD patients treated with (A) rituximab- and non–rituximab-based therapy; (B) rituximab ± DLI therapy, rituximab alone versus DLI alone: P = .015; rituximab alone versus DLI plus rituximab: P = .036; rituximab versus non-rituximab/non-DLI: P = .062.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions